Hair Study
RCH-01: Androgenetic Alopecia
In 2017, RepliCel completed a phase 1 human clinical trial of RCH-01 in patients with androgenetic alopecia. The study’s results supported the product’s safety and provided encouraging indications of its efficacy in terms of minimizing hair loss and increasing hair density in a subset of patients.
RepliCel continues to advance its cell therapy and dermal injection programs through ongoing research and development.
Peer-reviewed Papers
RCH-01 for Pattern Baldness
Cell Movement in the Hair Follicle Dermis – More Than a Two-Way Street?
De Novo Production of Dermal Papilla Cells during the Anagen Phase of the Hair Cycle